Daratumumab Biosimilar uses the same protein sequences as the therapeutic antibody daratumumab.Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody. Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.
